Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression

  1. Gordon W. McLean1,8,
  2. Noboru H. Komiyama3,4,
  3. Bryan Serrels1,
  4. Hidefumi Asano4,7,
  5. Louise Reynolds5,
  6. Francesco Conti5,
  7. Kairbaan Hodivala-Dilke5,
  8. Daniel Metzger6,
  9. Pierre Chambon6,
  10. Seth G.N. Grant3,4, and
  11. Margaret C. Frame1,2
  1. 1The Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, G61 1BD, United Kingdom; 2Institute of Biological and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom; 3Wellcome Trust Sanger Institute, Cambridgeshire, CB10 1XA, United Kingdom; 4Division of Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ, United Kingdom; 5The London Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, London, EC1M 6BQ, United Kingdom; 6Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Collège de France, 67404 Illkirch Cedex, Strasbourg, France

Abstract

We have generated mice with a floxed fak allele under the control of keratin-14-driven Cre fused to a modified estrogen receptor (CreERT2). 4-Hydroxy-tamoxifen treatment induced fak deletion in the epidermis, and suppressed chemically induced skin tumor formation. Loss of fak induced once benign tumors had formed inhibited malignant progression. Although fak deletion was associated with reduced migration of keratinocytes in vitro, we found no effect on wound re-epithelialization in vivo. However, increased keratinocyte cell death was observed after fak deletion in vitro and in vivo. Our work provides the first experimental proof implicating FAK in tumorigenesis, and this is associated with enhanced apoptosis.

Keywords

Footnotes

  • Supplemental material is available at http://www.genesdev.org.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.316304.

  • 8 Corresponding author. E-MAIL g.mclean{at}beatson.gla.ac.uk; FAX 44-141-942-6521.

  • 7 Present address: Chiba-City Kaihin Hospital, 3-31-1 Isobe, Mihama-Ku, Chiba City, Japan.

    • Accepted October 14, 2004.
    • Received July 1, 2004.
| Table of Contents

Life Science Alliance